78 related articles for article (PubMed ID: 18754442)
1. [Epidermal growth factor receptor and phosphorylated Akt protein expression in non-small-cell lung cancer].
Zhou ZL; Yang F; Jiang GC; Huang YQ; Fu J; Wang J
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1062-5. PubMed ID: 18754442
[TBL] [Abstract][Full Text] [Related]
2. Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC.
Mukohara T; Kudoh S; Matsuura K; Yamauchi S; Kimura T; Yoshimura N; Kanazawa H; Hirata K; Inoue K; Wanibuchi H; Fukushima S; Yoshikawa J
Anticancer Res; 2004; 24(1):11-7. PubMed ID: 15015570
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
Cappuzzo F; Hirsch FR; Rossi E; Bartolini S; Ceresoli GL; Bemis L; Haney J; Witta S; Danenberg K; Domenichini I; Ludovini V; Magrini E; Gregorc V; Doglioni C; Sidoni A; Tonato M; Franklin WA; Crino L; Bunn PA; Varella-Garcia M
J Natl Cancer Inst; 2005 May; 97(9):643-55. PubMed ID: 15870435
[TBL] [Abstract][Full Text] [Related]
4. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC).
Mukohara T; Kudoh S; Yamauchi S; Kimura T; Yoshimura N; Kanazawa H; Hirata K; Wanibuchi H; Fukushima S; Inoue K; Yoshikawa J
Lung Cancer; 2003 Aug; 41(2):123-30. PubMed ID: 12871775
[TBL] [Abstract][Full Text] [Related]
5. Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer.
Shah A; Swain WA; Richardson D; Edwards J; Stewart DJ; Richardson CM; Swinson DE; Patel D; Jones JL; O'Byrne KJ
Clin Cancer Res; 2005 Apr; 11(8):2930-6. PubMed ID: 15837744
[TBL] [Abstract][Full Text] [Related]
6. EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: a positive association.
Berghmans T; Mascaux C; Haller A; Meert AP; Van Houtte P; Sculier JP
Lung Cancer; 2008 Oct; 62(1):35-44. PubMed ID: 18355939
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer.
Yip PY; Cooper WA; Kohonen-Corish MR; Lin BP; McCaughan BC; Boyer MJ; Kench JG; Horvath LG
J Clin Pathol; 2014 Apr; 67(4):333-40. PubMed ID: 24265323
[TBL] [Abstract][Full Text] [Related]
9. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
Park S; Choi YL; Sung CO; An J; Seo J; Ahn MJ; Ahn JS; Park K; Shin YK; Erkin OC; Song K; Kim J; Shim YM; Han J
Histol Histopathol; 2012 Feb; 27(2):197-207. PubMed ID: 22207554
[TBL] [Abstract][Full Text] [Related]
10. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
11. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.
Na II; Rho JK; Choi YJ; Kim CH; Park JH; Koh JS; Ryoo BY; Yang SH; Lee JC
Lung Cancer; 2007 Jul; 57(1):96-102. PubMed ID: 17337084
[TBL] [Abstract][Full Text] [Related]
12. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.
Sonobe M; Nakagawa M; Takenaka K; Katakura H; Adachi M; Yanagihara K; Otake Y; Wada H; Tanaka F
J Surg Oncol; 2007 Jan; 95(1):63-9. PubMed ID: 17192868
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma.
Tsurutani J; Steinberg SM; Ballas M; Robertson M; LoPiccolo J; Soda H; Kohno S; Egilsson V; Dennis PA
Lung Cancer; 2007 Jan; 55(1):115-21. PubMed ID: 17097759
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK
J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947
[TBL] [Abstract][Full Text] [Related]
15. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
[TBL] [Abstract][Full Text] [Related]
16. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; Ludovini V; Gregorc V; Ligorio C; Cancellieri A; Damiani S; Spreafico A; Paties CT; Lombardo L; Calandri C; Bellezza G; Tonato M; Crinò L
J Natl Cancer Inst; 2004 Aug; 96(15):1133-41. PubMed ID: 15292385
[TBL] [Abstract][Full Text] [Related]
17. [Expression and clinical significance of a disintegrin and metalloprotease 8 (ADAM8) and epidermal growth factor receptor (EGFR) in non-small cell lung cancer].
Wu GC; Hu HC; Shi MH
Ai Zheng; 2008 Aug; 27(8):874-8. PubMed ID: 18710625
[TBL] [Abstract][Full Text] [Related]
18. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
[TBL] [Abstract][Full Text] [Related]
19. Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer.
Kawai H; Ishii A; Washiya K; Konno T; Kon H; Yamaya C; Ono I; Ogawa J
Anticancer Res; 2005; 25(6C):4693-8. PubMed ID: 16334162
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Zhang X; Fan J; Li Y; Lin S; Shu P; Ni J; Qin S; Zhang Z
Tumour Biol; 2016 Jan; 37(1):1061-9. PubMed ID: 26269114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]